Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAYZENT vs FINGOLIMOD HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
0.5 mg orally once daily
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Primarily metabolized by CYP3A4 and to a minor extent by CYP2C8; also undergoes reversible phosphorylation to active metabolite.
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
>99.9% bound to plasma proteins, primarily albumin and lipoproteins.
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
Very large, approximately 3000 L (≈43 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
Oral bioavailability is approximately 84% (absolute); food does not significantly affect absorption.
Oral bioavailability is approximately 93% (range 80–100%).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Severe renal impairment (GFR <30 m L/min): not recommended due to limited data.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Mild to moderate hepatic impairment (Child-Pugh class A or B): no dose adjustment needed.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
No specific dose adjustment recommended; use with caution due to increased risk of infections and arrhythmias.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
Increased risk of infections due to dose-dependent reduction in peripheral lymphocyte count; live attenuated vaccines should be avoided during and for 4 weeks after treatment.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
Increased risk of infections,Cardiovascular effects (bradyarrhythmia, AV block, QT prolongation),Respiratory effects (decline in pulmonary function),Hepatic injury,Fetal risk (teratogenicity),Macular edema,Posterior reversible encephalopathy syndrome (PRES),Increased risk of skin malignancies,Hypertension
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
Recent myocardial infarction, unstable angina, stroke/TIA, decompensated heart failure, or Mobitz type II second- or third-degree AV block in patients not paced,Severe active infections,Active malignancies except basal cell carcinoma
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
Grapefruit juice may increase siponimod exposure; avoid concurrent consumption. No other significant food interactions reported; administer with or without food.
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed at maternal exposures below the human therapeutic dose. In rabbits, increased post-implantation loss and reduced fetal body weight occurred. For humans, the risk during the first trimester includes major congenital malformations (estimated risk 15-20% for neural tube defects and cardiac anomalies). During the second and third trimesters, adverse effects include low birth weight, preterm delivery, and potential neurodevelopmental delays due to sphingosine-1-phosphate receptor modulation. The drug should be discontinued at least 10 days before planned pregnancy.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
Siponimod is excreted in animal milk; human data are absent. No M/P ratio is available. Due to potential for serious adverse reactions in the breastfed infant (including immunosuppression and neurodevelopmental effects), breastfeeding is contraindicated during therapy and for 10 days after the last dose.
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
Pregnancy causes increased volume of distribution, enhanced CYP3A4 activity, and potential changes in protein binding that may affect siponimod pharmacokinetics. Although no specific dose adjustment studies have been conducted in pregnant women, the drug is contraindicated in pregnancy; therefore, no dose adjustments are recommended. The drug should be discontinued at least 10 days before a planned pregnancy or immediately upon discovery of pregnancy.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
Initiate titration pack to minimize cardiac effects; obtain baseline ECG, LFTs, and ophthalmic exam. Monitor for bradycardia, AV block, macular edema, and infections. Avoid live vaccines. Check CYP2C9 genotype before dosing.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
Do not stop taking MAYZENT without consulting your doctor, as severe disease worsening can occur.,Report any signs of infection, vision changes, or slow/irregular heartbeat immediately.,Use effective contraception during treatment and for 3 months after stopping due to potential fetal harm.,Avoid grapefruit juice, as it may increase drug levels and side effects.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAYZENT vs FINGOLIMOD HYDROCHLORIDE, answered by our medical review team.
MAYZENT is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.. FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAYZENT and FINGOLIMOD HYDROCHLORIDE depend on the specific clinical indication. These are both Sphingosine 1-Phosphate Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAYZENT is: 0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.. The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAYZENT and FINGOLIMOD HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAYZENT is classified as Category C. Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed . FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.